Results-Hospital mortality was 9-3% (14/150). Total follow up was 696 patientyears (mean 4-7 years per patient). Linearised rates (events per 100 patientyears (SEM)) for postoperative complications for patients with isolated mitral valve replacement, isolated aortic valve replacement, and multiple valve replacement were, respectively: late mortality: 4*7 (1-6), 3-3 (0.9), and 4 9 (1.9); thromboembolism: 5-8 (1.8), 3-0 (0.9), and 2X8 (1X4); valve thrombosis: 1-0 (0.7), 0-3 (0-3), and 0 7 (0.7); structuralfailure: 5-8 (1.7), 1-9 (0.7), and 7-1 (2.2). Actuarial freedom from complications at nine years (70% confidence interval) was: late mortality: 61 (9)%, 57 (13)%, and 59 (12)%; thromboembolism and valve thrombosis: 71 (9)%, 79 (6)%, and 81 (8)%; structural failure: 33 (14)%, 50 (16)%, and 12 (14)%; all valve related morbiditylmortality: 31 (10)%, 21 (11)%, and 7 (9)%. Stent fractures appeared in 11 of 17 explanted prostheses; actuarial freedom from stent fracture at nine years was 66 (12)%. Conclusions-The Wessex bioprosthesis is associated with high thrombogenicity, early structural dysfunction, and a high valve related morbidity/mortality which justifies very close follow up of patients fitted with them.
The Wessex porcine heart valve was the latest European initiative to develop a conventional porcine bioprosthesis. The Complications appearing with a non-biased time course were expressed by linearised rates. Actuarial analysis was performed using the Late mortality 9 9 4-7 (1-6) 12 12 3-3 (0-9) 7 7 4-9 (1-9) Valve related mortality 6 6 3-1 (1-3) 5-8 (1-7) 7 7 1-9 (0-7) 10 10 7-1 (2 2) Non-structural dysfunction 2 2 1-6 (0 9) 5 5 1-6 (0-7) 4 4 3-5 (1-6) Reoperation 12 12 6-3 (1-8) 10 10 2-7 (0-9) 9 9 6-4 (2-1) (14) thromboembolic events, which were lethal on 65 (13) 3) . Forty valves were explanted during the follow up and 17 were recovered for study. Stent fractures were present in 11 of these (nine aortic and two mitral), which were explanted at a mean of 70 (SD 31) months (range 10 to 101 months) after the initial surgery (fig 4) . All nine aortic prostheses were explanted for various reasons other than stent fracture. Both mitral valves presented severe regurgitation 50 (16) due to a tear of a cusp and the deformity produced by the ruptured stent. All affected specimens presented multiple fractures (mean of 33 (14) 3-6 (SD 1-6) per valve), which characteristically appeared at the base of the post arch or at the commissural portion of the basal ring. The 12 (14) estimated actuarial probability of freedom from stent fracture in either mitral or aortic prostheses at nine years of follow up (70% CI) was 66 (12)%. their prostheses ( Figure 5 Freedom from reoperation. Actuarial probability at 9years'folow up. Er bars = 70% confidence interval.
Discussion
The Wessex bioprosthesis was designed in the early 1980s, with the aim of developing a totally European porcine heart valve that would take advantage of the knowledge and technical refinements available at the time in le valve this field of research. The device was made available for clinical use in 1982.' During its manufacturing process, selected porcine aortic nolysis roots were fixed in glutaraldehyde to a final ripros-concentration of 0-2% and with a head presid two sure of 50 mm Hg, and mounted on flexible is and plastic stents. A strip bias of glutaraldehyde I one treated porcine parietal pericardium, with its f free-visceral surface exposed, was applied to the Lt nine outflow edge of the device, purportedly to % for reduce the eventual abrasion associated to the % for contact at this level between the leaflets and the free edges and the frame.' The cast stent was made out of Hostafom C2702 1, an acetylcopolymer not previously used in prosthetic ion of heart valve manufacture and chosen for its in vitro creep and mechanical fatigue resistance properties.' Initial in vitro studies showed a satisfactory hydrodynamic performance, comparable to other bioprostheses available at the time,5 and the short term follow up studies were encouraging.26 However, to our knowledge no further follow up research has been carried out on this valve, not even by the original investigators. Our study is thus the first attempt to deter-51 (12) mine the mid to long term clinical perfor-50(16) mance of this bioprosthesis, and we believe that the results obtained-despite the fact that the series is not a large one-are significant enough as to justify this report.
The first relevant feature in our series is an 16(19) unusually high incidence of thromboembolic phenomena and valve thrombosis. The incidence of this complication is significantly higher than has been reported for other porcine bioprostheses,7-"I and even higher than the figures obtained with some modem rror mechanical prostheses. 12-15 Also, the results with other porcine bioprostheses in this 
